Search Results - "Macaulay, Charles W"
-
1
Follicular Dendritic Cells Modulate Germinal Center B Cell Diversity through FcγRIIB
Published in Cell reports (Cambridge) (26-11-2019)“…Follicular dendritic cells (FDCs), a rare and enigmatic stromal cell type in the B cell follicles of secondary lymphoid organs, store and present antigen to B…”
Get full text
Journal Article -
2
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA
Published in Nature biotechnology (01-12-2021)“…Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the limited sensitivity of current detection methods reduces its utility…”
Get full text
Journal Article -
3
Inferring gene expression from cell-free DNA fragmentation profiles
Published in Nature biotechnology (01-04-2022)“…Profiling of circulating tumor DNA (ctDNA) in the bloodstream shows promise for noninvasive cancer detection. Chromatin fragmentation features have previously…”
Get full text
Journal Article -
4
Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas
Published in Journal of clinical oncology (20-03-2023)“…Clinical outcomes of patients with CNS lymphomas (CNSLs) are remarkably heterogeneous, yet identification of patients at high risk for treatment failure is…”
Get full text
Journal Article -
5
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
Published in Cancer cell (09-01-2023)“…Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19 chimeric antigen receptor (CAR19) T cells relapse. To characterize…”
Get full text
Journal Article -
6
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma
Published in Journal of clinical oncology (10-08-2021)“…Patients with Diffuse Large B-cell Lymphoma (DLBCL) in need of immediate therapy are largely under-represented in clinical trials. The diagnosis-to-treatment…”
Get full text
Journal Article -
7
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
Published in Blood advances (11-04-2023)“…•Lenalidomide, obintuzumab, and CHOP chemotherapy are efficacious and well tolerated treatments for newly diagnosed DLBCL.•LO-CHOP led to high molecular…”
Get full text
Journal Article -
8